Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
The tests offered include Shield™ for cancer screening and early detection, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers.
- The tests offered include Shield™ for cancer screening and early detection, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers.
- This agreement provides Hikma with exclusive rights to commercialize Guardant Health's products in a majority of countries in the MENA region.
- Guardant Health serves more than 60 countries globally with its tests, and this partnership with Hikma will improve access to Guardant's next-generation sequencing (NGS) tests in the Middle East and North Africa, where cancer cases are estimated to double by the year 2040.
- Ultimately, our goal is to make cancer screening easy and effective so that we can detect cancer earlier when it's most treatable."